地舒單抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "地舒單抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

11web.archive.org

1^st place

10nih.gov

4^th place

5^th place

8doi.org

2^nd place

23^rd place

1landesbioscience.com

low place

1amgen.com

low place

1europa.eu

68^th place

209^th place

1drugs.com

399^th place

208^th place

1harvard.edu

18^th place

57^th place

1todaysgeriatricmedicine.com

low place

1urotoday.com

low place

1nytimes.com

7^th place

31^st place

1biosciencetechnology.com

low place

1genengnews.com

low place

1medpagetoday.com

9,274^th place

low place

1cancer.gov

1,684^th place

696^th place

amgen.com

Prolia (denosumab). Products. Amgen. [6 May 2012]. （原始内容存档于2015-09-29）.

biosciencetechnology.com

Matthew Perrone. FDA clears Amgen's bone-strengthening drug Prolia. BioScience Technology. June 2, 2010 [June 2, 2010]. （原始内容存档于August 27, 2010）.

cancer.gov

FDA Approval for Denosumab. [2021-04-29]. （原始内容存档于2015-04-06）.

doi.org

Denosumab. mAbs. 2009, 1 (3): 210–5 [2021-04-29]. PMC 2726593 . PMID 20065634. doi:10.4161/mabs.1.3.8592. （原始内容存档于2012-03-08）. 引用错误：带有name属性“pmid_20065634”的<ref>标签用不同内容定义了多次
Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine. February 2006, 354 (8): 821–31. PMID 16495394. doi:10.1056/NEJMoa044459.
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. November 2012, 48 (16): 3082–92. PMID 22975218. doi:10.1016/j.ejca.2012.08.002.
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Current Medical Research and Opinion. March 2013, 29 (3): 205–16. PMID 23297819. doi:10.1185/03007995.2013.763779.
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. March 2017, 65 (3): 490–495. PMC 5358515 . PMID 28304090. doi:10.1111/jgs.14668.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. August 2009, 361 (8): 756–65. Bibcode:10.1.1.472.3489 请检查|bibcode=值 (帮助). PMID 19671655. doi:10.1056/NEJMoa0809493.
Increasing options for the treatment of osteoporosis. The New England Journal of Medicine. August 2009, 361 (8): 818–20. PMC 3901579 . PMID 19671654. doi:10.1056/NEJMe0905480.
Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Current Osteoporosis Reports. August 2017, 15 (4): 283–292. PMC 5554707 . PMID 28643220. doi:10.1007/s11914-017-0380-1.

drugs.com

Denosumab. The American Society of Health-System Pharmacists. [Mar 16, 2015]. （原始内容存档于2021-04-30）.

europa.eu

ema.europa.eu

European Public Assessment Report (EPAR) for Prolia. (PDF). European Medicines Agency. October 16, 2014 [2021-04-29]. （原始内容 (PDF)存档于2016-03-04）. 引用错误：带有name属性“EMEA”的<ref>标签用不同内容定义了多次

genengnews.com

Amgen's Denosumab Cleared by FDA for Second Indication. 19 Nov 2010 [2021-04-29]. （原始内容存档于2018-04-07）.

harvard.edu

ui.adsabs.harvard.edu

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. August 2009, 361 (8): 756–65. Bibcode:10.1.1.472.3489 请检查|bibcode=值 (帮助). PMID 19671655. doi:10.1056/NEJMoa0809493.

landesbioscience.com

Denosumab. mAbs. 2009, 1 (3): 210–5 [2021-04-29]. PMC 2726593 . PMID 20065634. doi:10.4161/mabs.1.3.8592. （原始内容存档于2012-03-08）. 引用错误：带有name属性“pmid_20065634”的<ref>标签用不同内容定义了多次

medpagetoday.com

FDA Approves Denosumab for Osteoporosis. 2 June 2010 [2021-04-29]. （原始内容存档于2018-06-13）.

nih.gov

ncbi.nlm.nih.gov

Denosumab. mAbs. 2009, 1 (3): 210–5 [2021-04-29]. PMC 2726593 . PMID 20065634. doi:10.4161/mabs.1.3.8592. （原始内容存档于2012-03-08）. 引用错误：带有name属性“pmid_20065634”的<ref>标签用不同内容定义了多次
Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine. February 2006, 354 (8): 821–31. PMID 16495394. doi:10.1056/NEJMoa044459.
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. November 2012, 48 (16): 3082–92. PMID 22975218. doi:10.1016/j.ejca.2012.08.002.
Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. International Journal of Clinical and Experimental Pathology. 2014, 7 (5): 2113–22. PMC 4069896 . PMID 24966919.
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Current Medical Research and Opinion. March 2013, 29 (3): 205–16. PMID 23297819. doi:10.1185/03007995.2013.763779.
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. March 2017, 65 (3): 490–495. PMC 5358515 . PMID 28304090. doi:10.1111/jgs.14668.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. August 2009, 361 (8): 756–65. Bibcode:10.1.1.472.3489 请检查|bibcode=值 (帮助). PMID 19671655. doi:10.1056/NEJMoa0809493.
Increasing options for the treatment of osteoporosis. The New England Journal of Medicine. August 2009, 361 (8): 818–20. PMC 3901579 . PMID 19671654. doi:10.1056/NEJMe0905480.
EntrezGene 8600 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11; Homo sapiens
also known as RANKL. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response.
Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Current Osteoporosis Reports. August 2017, 15 (4): 283–292. PMC 5554707 . PMID 28643220. doi:10.1007/s11914-017-0380-1.

nytimes.com

Pollack, Andrew. F.D.A. Says No to an Amgen Bone Drug. The New York Times. 19 October 2009 [2021-04-29]. （原始内容存档于2018-01-27）.

todaysgeriatricmedicine.com

Injectable Prolia — Osteoporosis Update. [2021-04-29]. （原始内容存档于2021-03-09）.

urotoday.com

Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting. PRNewswire/FirstCall. August 13, 2009 [September 17, 2009]. （原始内容存档于November 3, 2013）.

web.archive.org

Denosumab. mAbs. 2009, 1 (3): 210–5 [2021-04-29]. PMC 2726593 . PMID 20065634. doi:10.4161/mabs.1.3.8592. （原始内容存档于2012-03-08）. 引用错误：带有name属性“pmid_20065634”的<ref>标签用不同内容定义了多次
Prolia (denosumab). Products. Amgen. [6 May 2012]. （原始内容存档于2015-09-29）.
European Public Assessment Report (EPAR) for Prolia. (PDF). European Medicines Agency. October 16, 2014 [2021-04-29]. （原始内容 (PDF)存档于2016-03-04）. 引用错误：带有name属性“EMEA”的<ref>标签用不同内容定义了多次
Denosumab. The American Society of Health-System Pharmacists. [Mar 16, 2015]. （原始内容存档于2021-04-30）.
Injectable Prolia — Osteoporosis Update. [2021-04-29]. （原始内容存档于2021-03-09）.
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting. PRNewswire/FirstCall. August 13, 2009 [September 17, 2009]. （原始内容存档于November 3, 2013）.
Pollack, Andrew. F.D.A. Says No to an Amgen Bone Drug. The New York Times. 19 October 2009 [2021-04-29]. （原始内容存档于2018-01-27）.
Matthew Perrone. FDA clears Amgen's bone-strengthening drug Prolia. BioScience Technology. June 2, 2010 [June 2, 2010]. （原始内容存档于August 27, 2010）.
Amgen's Denosumab Cleared by FDA for Second Indication. 19 Nov 2010 [2021-04-29]. （原始内容存档于2018-04-07）.
FDA Approves Denosumab for Osteoporosis. 2 June 2010 [2021-04-29]. （原始内容存档于2018-06-13）.
FDA Approval for Denosumab. [2021-04-29]. （原始内容存档于2015-04-06）.